Michael H. Kroll MDProfessor of Medicine and Chief, Section of Benign Hematology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dr. Michael Kroll is a hematologist and oncologist practicing in Houston, Texas. He is Professor of Medicine and Chief of the Section of Benign Hematology at the University of Texas MD Anderson Cancer Center (UTMDACC). His basic research background is in mechanisms of platelet-dependent thrombosis, and his academic clinical niche is benign hematology, hemostasis and thrombosis. His group’s research activities focus on mechanisms of cancer- and stem cell transplant–associated thrombotic microangiopathy, the prevention and treatment of venous thromboembolism in cancer patients, and mechanisms of cancer-induced venous thrombosis.
Dr. Kroll is intimately involved in fellowship training, co-directs UTMDACC’s Anticoagulant Stewardship Program, has published over 100 manuscripts in peer-reviewed journals, lectures world-wide over a dozen times per year, serves on 2 federal grant review committees, has received several awards for education and leadership, and continues to serve The American Society of Hematology in various capacities.
Dr. Kroll received his medical degree from Cornell. He underwent residency training in internal medicine at Brown University and completed his fellowship in hematology/oncology at Harvard Medical School–Brigham & Women's Hospital.
Recent Contributions to PracticeUpdate:
- Predictive Model for Bone Marrow Disease in Cytopenia Based on Noninvasive Procedures
- Avatrombopag for Chemotherapy-Induced Thrombocytopenia in Patients With Non-Haematological Malignancies
- Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination
- Impact of COVID-19 Vaccination on Patients With a History of Heparin-Induced Thrombocytopenia
- Risk Factors for Recurrence of Venous Thromboembolism During Pregnancy
- Symptom Burden and Quality of Life in High-Risk ET and PV Treated With Hydroxyurea or Pegylated Interferon Alfa-2a
- MDM2 Antagonist Idasanutlin in Polycythemia Vera
- Long-Term Adherence to DOACs and Clinical Outcomes in Patients With Atrial Fibrillation
- Switching From VKAs to DOACs in Non-Valvular Atrial Fibrillation
- 2021 Top Story in Benign Hematology: Hematological Complications of COVID-19 Vaccination